nach oben

Arthritis Research & Therapy

Erschienen in:

01.04.2010 | Review

Genetic associations in type I interferon related pathways with autoimmunity

verfasst von: Angélica M Delgado-Vega, Marta E Alarcón-Riquelme, Sergey V Kozyrev

Erschienen in: Arthritis Research & Therapy | Sonderheft 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Type I interferons play an outstanding role in innate and adaptive immunity by enhancing functions of dendritic cells, inducing differentiation of monocytes, promoting immunoglobulin class switching in B cells and stimulating effector functions of T cells. The increased production of IFNα/β by plasmacytoid dendritic cells could be responsible for not only efficient antiviral defence, but it also may be a pathological factor in the development of various autoimmune disorders. The first evidence of a genetic link between type I interferons and autoimmune diseases was the observation that elevated IFNα activity is frequently detected in the sera of patients with systemic lupus erythematosus, and that this trait shows high heritability and familial aggregation in their first-degree healthy relatives. To date, a number of genes involved in interferon signalling have been associated with various autoimmune diseases. Patients with systemic lupus erythematosus, Sjögren's syndrome, dermatomyositis, psoriasis, and a fraction of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature. Here, in an attempt to understand the role of type I interferons in the pathogenesis of autoimmunity, we review the recent advances in the genetics of autoimmune diseases focusing on the association of genes involved in type I interferon pathways.

Pestka S, Krause CD, Walter MR: Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004, 202: 8-32. 10.1111/j.0105-2896.2004.00204.x.PubMed

Jaks E, Gavutis M, Uze G, Martal J, Piehler J: Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol. 2007, 366: 525-539. 10.1016/j.jmb.2006.11.053.PubMed

Diaz MO, Pomykala HM, Bohlander SK, Maltepe E, Malik K, Brownstein B, Olopade OI: Structure of the human type-I interferon gene cluster determined from a YAC clone contig. Genomics. 1994, 22: 540-552. 10.1006/geno.1994.1427.PubMed

Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, Cebon J: Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol. 1998, 161: 1947-1953.PubMed

Gallucci S, Lolkema M, Matzinger P: Natural adjuvants: endogenous activators of dendritic cells. Nat Med. 1999, 5: 1249-1255. 10.1038/15200.PubMed

Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, Borrow P, Tough DF: Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood. 2002, 99: 3263-3271. 10.1182/blood.V99.9.3263.PubMed

Ito T, Amakawa R, Inaba M, Ikehara S, Inaba K, Fukuhara S: Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol. 2001, 166: 2961-2969.PubMed

Ito T, Kanzler H, Duramad O, Cao W, Liu YJ: Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood. 2006, 107: 2423-2431. 10.1182/blood-2005-07-2709.PubMed

Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J: Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 2003, 19: 225-234. 10.1016/S1074-7613(03)00208-5.PubMed

10.

Nejentsev S, Walker N, Riches D, Egholm M, Todd JA: Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science. 2009, 324: 387-389. 10.1126/science.1167728.PubMedCentralPubMed

11.

Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, Hilbert DM: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999, 285: 260-263. 10.1126/science.285.5425.260.PubMed

12.

Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, Cerutti A: DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol. 2002, 3: 822-829. 10.1038/ni829.PubMedCentralPubMed

13.

Decalf J, Fernandes S, Longman R, Ahloulay M, Audat F, Lefrerre F, Rice CM, Pol S, Albert ML: Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. J Exp Med. 2007, 204: 2423-2437. 10.1084/jem.20070814.PubMedCentralPubMed

14.

Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, Giese T, Engelmann H, Endres S, Krieg AM, Hartmann G: Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001, 31: 3026-3037. 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H.PubMed

15.

Piqueras B, Connolly J, Freitas H, Palucka AK, Banchereau J: Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors. Blood. 2006, 107: 2613-2618. 10.1182/blood-2005-07-2965.PubMedCentralPubMed

16.

Penna G, Vulcano M, Roncari A, Facchetti F, Sozzani S, Adorini L: Cutting edge: differential chemokine production by myeloid and plasmacytoid dendritic cells. J Immunol. 2002, 169: 6673-6676.PubMed

17.

Megjugorac NJ, Young HA, Amrute SB, Olshalsky SL, Fitzgerald-Bocarsly P: Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells. J Leukoc Biol. 2004, 75: 504-514. 10.1189/jlb.0603291.PubMed

18.

Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF: Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol. 2005, 174: 4465-4469.PubMed

19.

Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF: Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001, 14: 461-470. 10.1016/S1074-7613(01)00126-1.PubMed

20.

Gisler RH, Lindahl P, Gresser I: Effects of interferon on antibody synthesis in vitro. J Immunol. 1974, 113: 438-444.PubMed

21.

Peters M, Ambrus JL, Zheleznyak A, Walling D, Hoofnagle JH: Effect of interferon-alpha on immunoglobulin synthesis by human B cells. J Immunol. 1986, 137: 3153-3157.PubMed

22.

Braun D, Caramalho I, Demengeot J: IFN-alpha/beta enhances BCR-dependent B cell responses. Int Immunol. 2002, 14: 411-419. 10.1093/intimm/14.4.411.PubMed

23.

Morikawa K, Kubagawa H, Suzuki T, Cooper MD: Recombinant interferon-alpha, -beta, and -gamma enhance the proliferative response of human B cells. J Immunol. 1987, 139: 761-766.PubMed

24.

Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U, Tough DF: Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol. 2006, 176: 2074-2078.PubMed

25.

Marrack P, Kappler J, Mitchell T: Type I interferons keep activated T cells alive. J Exp Med. 1999, 189: 521-530. 10.1084/jem.189.3.521.PubMedCentralPubMed

26.

Ruuth K, Carlsson L, Hallberg B, Lundgren E: Interferon-alpha promotes survival of human primary B-lymphocytes via phosphatidylinositol 3-kinase. Biochem Biophys Res Commun. 2001, 284: 583-586. 10.1006/bbrc.2001.5025.PubMed

27.

von Hoegen P, Zawatzky R, Schirrmacher V: Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta. Cell Immunol. 1990, 126: 80-90. 10.1016/0008-8749(90)90302-8.PubMed

28.

Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K: Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med. 2005, 202: 637-650. 10.1084/jem.20050821.PubMedCentralPubMed

29.

Lee CK, Rao DT, Gertner R, Gimeno R, Frey AB, Levy DE: Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol. 2000, 165: 3571-3577.PubMed

30.

Kamath AT, Sheasby CE, Tough DF: Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. J Immunol. 2005, 174: 767-776.PubMed

31.

Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L: Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med. 1999, 5: 405-411. 10.1038/7403.PubMed

32.

Gerosa F, Gobbi A, Zorzi P, Burg S, Briere F, Carra G, Trinchieri G: The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol. 2005, 174: 727-734.PubMed

33.

Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J: Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001, 294: 1540-1543. 10.1126/science.1064890.PubMed

34.

Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL: Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979, 301: 5-8. 10.1056/NEJM197907053010102.PubMed

35.

Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J: Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science. 1982, 216: 429-431. 10.1126/science.6176024.PubMed

36.

Ytterberg SR, Schnitzer TJ: Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum. 1982, 25: 401-406. 10.1002/art.1780250407.PubMed

37.

Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK: High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007, 8: 492-502. 10.1038/sj.gene.6364408.PubMedCentralPubMed

38.

Hooks JJ, Jordan GW, Cupps T, Moutsopoulos HM, Fauci AS, Notkins AL: Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum. 1982, 25: 396-400. 10.1002/art.1780250406.PubMed

39.

Gota C, Calabrese L: Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity. 2003, 36: 511-518. 10.1080/08916930310001605873.PubMed

40.

Ronnblom LE, Alm GV, Oberg KE: Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med. 1991, 115: 178-183.PubMed

41.

Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW: Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA. 2003, 100: 2610-2615. 10.1073/pnas.0337679100.PubMedCentralPubMed

42.

Alarcon-Segovia D: Shared autoimmunity: a concept for which the time has come. Autoimmunity. 2005, 38: 201-203. 10.1080/08916930500050285.PubMed

43.

Baechler EC, Batliwalla FM, Reed AM, Peterson EJ, Gaffney PM, Moser KL, Gregersen PK, Behrens TW: Gene expression profiling in human autoimmunity. Immunol Rev. 2006, 210: 120-137. 10.1111/j.0105-2896.2006.00367.x.PubMed

44.

Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ: The nature of the principal type 1 interferonproducing cells in human blood. Science. 1999, 284: 1835-1837. 10.1126/science.284.5421.1835.PubMed

45.

Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, Colonna M: Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999, 5: 919-923. 10.1038/11360.PubMed

46.

Rahman AH, Eisenberg RA: The role of toll-like receptors in systemic lupus erythematosus. Springer Semin Immunopathol. 2006, 28: 131-143. 10.1007/s00281-006-0034-3.PubMed

47.

Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G: Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 2002, 168: 4531-4537.PubMed

48.

Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S: Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004, 303: 1526-1529. 10.1126/science.1093620.PubMed

49.

Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, Liu YJ: Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001, 194: 863-869. 10.1084/jem.194.6.863.PubMedCentralPubMed

50.

Birmachu W, Gleason RM, Bulbulian BJ, Riter CL, Vasilakos JP, Lipson KE, Nikolsky Y: Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists. BMC Immunol. 2007, 8: 26-10.1186/1471-2172-8-26.PubMedCentralPubMed

51.

Kawai T, Adachi O, Ogawa T, Takeda K, Akira S: Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity. 1999, 11: 115-122. 10.1016/S1074-7613(00)80086-2.PubMed

52.

Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T: The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol. 2004, 5: 730-737. 10.1038/ni1087.PubMed

53.

Kang DC, Gopalkrishnan RV, Wu Q, Jankowsky E, Pyle AM, Fisher PB: mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc Natl Acad Sci USA. 2002, 99: 637-642. 10.1073/pnas.022637199.PubMedCentralPubMed

54.

Garcia MA, Meurs EF, Esteban M: The dsRNA protein kinase PKR: virus and cell control. Biochimie. 2007, 89: 799-811. 10.1016/j.biochi.2007.03.001.PubMed

55.

Hovanessian AG, Justesen J: The human 2'-5'oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2'-5' instead of 3'-5' phosphodiester bond formation. Biochimie. 2007, 89: 779-788. 10.1016/j.biochi.2007.02.003.PubMed

56.

Ishii KJ, Kawagoe T, Koyama S, Matsui K, Kumar H, Kawai T, Uematsu S, Takeuchi O, Takeshita F, Coban C, Akira S: TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature. 2008, 451: 725-729. 10.1038/nature06537.PubMed

57.

Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES: AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature. 2009, 458: 509-513. 10.1038/nature07710.PubMedCentralPubMed

58.

Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, Latz E, Fitzgerald KA: AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature. 2009, 458: 514-518. 10.1038/nature07725.PubMedCentralPubMed

59.

Roberts TL, Idris A, Dunn JA, Kelly GM, Burnton CM, Hodgson S, Hardy LL, Garceau V, Sweet MJ, Ross IL, Hume DA, Stacey KJ: HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science. 2009, 323: 1057-1060. 10.1126/science.1169841.PubMed

60.

Burckstummer T, Baumann C, Bluml S, Dixit E, Durnberger G, Jahn H, Planyavsky M, Bilban M, Colinge J, Bennett KL, Superti-Furga G: An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol. 2009, 10: 266-272. 10.1038/ni.1702.PubMed

61.

Muruve DA, Petrilli V, Zaiss AK, White LR, Clark SA, Ross PJ, Parks RJ, Tschopp J: The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature. 2008, 452: 103-107. 10.1038/nature06664.PubMed

62.

Lee HK, Lund JM, Ramanathan B, Mizushima N, Iwasaki A: Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science. 2007, 315: 1398-1401. 10.1126/science.1136880.PubMed

63.

Barnes BJ, Field AE, Pitha-Rowe PM: Virus-induced heterodimer formation between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and transcriptional activity of IFNA genes. J Biol Chem. 2003, 278: 16630-16641. 10.1074/jbc.M212609200.PubMed

64.

Barnes BJ, Kellum MJ, Field AE, Pitha PM: Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol Cell Biol. 2002, 22: 5721-5740. 10.1128/MCB.22.16.5721-5740.2002.PubMedCentralPubMed

65.

Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM: Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res. 2003, 63: 6424-6431.PubMed

66.

Barnes BJ, Moore PA, Pitha PM: Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem. 2001, 276: 23382-23390. 10.1074/jbc.M101216200.PubMed

67.

Izaguirre A, Barnes BJ, Amrute S, Yeow WS, Megjugorac N, Dai J, Feng D, Chung E, Pitha PM, Fitzgerald-Bocarsly P: Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J Leukoc Biol. 2003, 74: 1125-1138. 10.1189/jlb.0603255.PubMed

68.

Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, Ortmann WA, Koeuth T, Gonzalez Escribano MF, Pons-Estel B, Petri M, Daly M, Gregersen PK, Martin J, Altshuler D, Behrens TW, Alarcon-Riquelme ME: A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet. 2006, 38: 550-555. 10.1038/ng1782.PubMed

69.

Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, Sturfelt G, Jonsen A, Rantapaa-Dahlqvist S, Moller B, Kere J, Koskenmies S, Widen E, Eloranta ML, Julkunen H, Kristjansdottir H, Steinsson K, Alm G, Ronnblom L, Syvanen AC: Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet. 2005, 76: 528-537. 10.1086/428480.PubMedCentralPubMed

70.

Sigurdsson S, Padyukov L, Kurreeman FA, Liljedahl U, Wiman AC, Alfredsson L, Toes R, Ronnelid J, Klareskog L, Huizinga TW, Alm G, Syvanen AC, Ronnblom L: Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum. 2007, 56: 2202-2210. 10.1002/art.22704.PubMed

71.

Miceli-Richard C, Comets E, Loiseau P, Puechal X, Hachulla E, Mariette X: Association of an IRF5 gene functional polymorphism with Sjogren's syndrome. Arthritis Rheum. 2007, 56: 3989-3994. 10.1002/art.23142.PubMedCentralPubMed

72.

Dideberg V, Kristjansdottir G, Milani L, Libioulle C, Sigurdsson S, Louis E, Wiman AC, Vermeire S, Rutgeerts P, Belaiche J, Franchimont D, Van Gossum A, Bours V, Syvanen AC: An insertion-deletion polymorphism in the interferon regulatory factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Hum Mol Genet. 2007, 16: 3008-3016. 10.1093/hmg/ddm259.PubMed

73.

Kristjansdottir G, Sandling JK, Bonetti A, Roos IM, Milani L, Wang C, Gustafsdottir SM, Sigurdsson S, Lundmark A, Tienari PJ, Koivisto K, Elovaara I, Pirttila T, Reunanen M, Peltonen L, Saarela J, Hillert J, Olsson T, Landegren U, Alcina A, Fernandez O, Leyva L, Guerrero M, Lucas M, Izquierdo G, Matesanz F, Syvanen AC: Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J Med Genet. 2008, 45: 362-369. 10.1136/jmg.2007.055012.PubMedCentralPubMed

74.

Sigurdsson S, Goring HH, Kristjansdottir G, Milani L, Nordmark G, Sandling JK, Eloranta ML, Feng D, Sangster-Guity N, Gunnarsson I, Svenungsson E, Sturfelt G, Jonsen A, Truedsson L, Barnes BJ, Alm G, Ronnblom L, Syvanen AC: Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet. 2008, 17: 872-881. 10.1093/hmg/ddm359.PubMed

75.

Kozyrev SV, Alarcon-Riquelme ME: The genetics and biology of Irf5-mediated signaling in lupus. Autoimmunity. 2007, 40: 591-601. 10.1080/08916930701510905.PubMed

76.

Cunninghame Graham DS, Manku H, Wagner S, Reid J, Timms K, Gutin A, Lanchbury JS, Vyse TJ: Association of IRF5 in UK SLE families identifies a variant involved in polyadenylation. Hum Mol Genet. 2007, 16: 579-591. 10.1093/hmg/ddl469.PubMed

77.

Löfgren S, Yin H, Delgado-Vega AM, Sanchez E, Lewéen S, Pons-Estel BA, Witte T, D'Alfonso S, Ortego-Centeno N, Martin J, Alarcón-Riquelme ME, Kozyrev SV: Promoter insertion/deletion in the IRF5 gene is highly associated with susceptibility to SLE in distinct populations but exerts a modest effect on gene expression in PBMCs. J Rheumatol. 2010, 37: 3-10.3899/jrheum.090440.

78.

Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LR, Baechler EC, Plenge RM, Koeuth T, Ortmann WA, Hom G, Bauer JW, Gillett C, Burtt N, Cunninghame Graham DS, Onofrio R, Petri M, Gunnarsson I, Svenungsson E, Ronnblom L, Nordmark G, Gregersen PK, Moser K, Gaffney PM, Criswell LA, Vyse TJ, Syvanen AC, Bohjanen PR, Daly MJ, Behrens TW, Altshuler D: Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci USA. 2007, 104: 6758-6763. 10.1073/pnas.0701266104.PubMedCentralPubMed

79.

Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK: Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 2008, 58: 2481-2487. 10.1002/art.23613.PubMedCentralPubMed

80.

Reddy MV, Velazquez-Cruz R, Baca V, Lima G, Granados J, Orozco L, Alarcon-Riquelme ME: Genetic association of IRF5 with SLE in Mexicans: higher frequency of the risk haplotype and its homozygozity than Europeans. Hum Genet. 2007, 121: 721-727. 10.1007/s00439-007-0367-6.PubMed

81.

Kawai T, Akira S: TLR signaling. Cell Death Differ. 2006, 13: 816-825. 10.1038/sj.cdd.4401850.PubMed

82.

Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, Pitha PM, Fitzgerald KA, Golenbock DT: The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem. 2005, 280: 17005-17012. 10.1074/jbc.M412584200.PubMed

83.

Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, Kano S, Honda K, Ohba Y, Mak TW, Taniguchi T: Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature. 2005, 434: 243-249. 10.1038/nature03308.PubMed

84.

Calvo-Alen J, Reveille JD, Rodriguez-Valverde V, McGwin G, Baethge BA, Friedman AW, Alarcon GS: Clinical, immunogenetic and outcome features of Hispanic systemic lupus erythematosus patients of different ethnic ancestry. Lupus. 2003, 12: 377-385. 10.1191/0961203303lu372oa.PubMed

85.

Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, Tsao BP, Vyse TJ, Langefeld CD, Nath SK, Guthridge JM, Cobb BL, Mirel DB, Marion MC, Williams AH, Divers J, Wang W, Frank SG, Namjou B, Gabriel SB, Lee AT, Gregersen PK, Behrens TW, Taylor KE, Fernando M, Zidovetzki R, Gaffney PM, Edberg JC, Rioux JD, Ojwang JO, et al: Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008, 40: 204-210. 10.1038/ng.81.PubMedCentralPubMed

86.

Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X, Ortmann W, Kosoy R, Ferreira RC, Nordmark G, Gunnarsson I, Svenungsson E, Padyukov L, Sturfelt G, Jonsen A, Bengtsson AA, Rantapaa-Dahlqvist S, Baechler EC, Brown EE, Alarcon GS, Edberg JC, Ramsey-Goldman R, McGwin G, Reveille JD, Vila LM, Kimberly RP, Manzi S, Petri MA, Lee A, Gregersen PK, et al: A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet. 2009, 41: 1228-1233. 10.1038/ng.468.PubMedCentralPubMed

87.

International HapMap Project. [http://hapmap.ncbi.nlm.nih.gov/]

88.

Akahoshi M, Nakashima H, Sadanaga A, Miyake K, Obara K, Tamari M, Hirota T, Matsuda A, Shirakawa T: Promoter polymorphisms in the IRF3 gene confer protection against systemic lupus erythematosus. Lupus. 2008, 17: 568-574. 10.1177/0961203308089340.PubMed

89.

Sanchez E, Gonzalez-Gay MA, Callejas-Rubio JL, Ortego-Centeno N, Sabio JM, Jimenez-Alonso J, Mico L, Suarez A, Gutierrez C, de Ramon E, Camps M, Garcia-Portales R, Tolosa C, Lopez-Nevot MA, Sanchez-Roman J, Hernandez FJ, Gonzalez-Escribano MF, Martin J: No evidence for genetic association of interferon regulatory factor 3 in systemic lupus erythematosus. Lupus. 2009, 18: 230-234. 10.1177/0961203308096256.PubMed

90.

De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT, Piccio L, Raychaudhuri S, Tran D, Aubin C, Briskin R, Romano S, Baranzini SE, McCauley JL, Pericak-Vance MA, Haines JL, Gibson RA, Naeglin Y, Uitdehaag B, Matthews PM, Kappos L, Polman C, McArdle WL, Strachan DP, Evans D, Cross AH, Daly MJ, Compston A, Sawcer SJ, Weiner HL, et al: Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009, 41: 776-782. 10.1038/ng.401.PubMedCentralPubMed

91.

Baldwin AS: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996, 14: 649-683. 10.1146/annurev.immunol.14.1.649.PubMed

92.

Li Q, Verma IM: NF-κB regulation in the immune system. Nat Rev Immunol. 2002, 2: 725-734. 10.1038/nri910.PubMed

93.

Gregersen PK, Amos CI, Lee AT, Lu Y, Remmers EF, Kastner DL, Seldin MF, Criswell LA, Plenge RM, Holers VM, Mikuls TR, Sokka T, Moreland LW, Bridges SL, Xie G, Begovich AB, Siminovitch KA: REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat Genet. 2009, 41: 820-823. 10.1038/ng.395.PubMedCentralPubMed

94.

Liou HC, Sha WC, Scott ML, Baltimore D: Sequential induction of NF-kappa B/Rel family proteins during B-cell terminal differentiation. Mol Cell Biol. 1994, 14: 5349-5359.PubMedCentralPubMed

95.

Kontgen F, Grumont RJ, Strasser A, Metcalf D, Li R, Tarlinton D, Gerondakis S: Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev. 1995, 9: 1965-1977. 10.1101/gad.9.16.1965.PubMed

96.

Owyang AM, Tumang JR, Schram BR, Hsia CY, Behrens TW, Rothstein TL, Liou HC: c-Rel is required for the protection of B cells from antigen receptor-mediated, but not Fas-mediated, apoptosis. J Immunol. 2001, 167: 4948-4956.PubMed

97.

Grumont R, Hochrein H, O'Keeffe M, Gugasyan R, White C, Caminschi I, Cook W, Gerondakis S: c-Rel regulates interleukin 12 p70 expression in CD8(+) dendritic cells by specifically inducing p35 gene transcription. J Exp Med. 2001, 194: 1021-1032. 10.1084/jem.194.8.1021.PubMedCentralPubMed

98.

Mise-Omata S, Kuroda E, Niikura J, Yamashita U, Obata Y, Doi TS: A proximal kappaB site in the IL-23 p19 promoter is responsible for RelA- and c-Rel-dependent transcription. J Immunol. 2007, 179: 6596-6603.PubMed

99.

Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, Silverberg MS, Duerr RH, Cho JH, Gregersen PK, Wu Y, Achkar JP, Dassopoulos T, Mezey E, Bayless TM, Nouvet FJ, Brant SR: Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet. 2004, 13: 35-45. 10.1093/hmg/ddh008.PubMed

100.

Katarina K, Daniela P, Peter N, Marianna R, Pavlina C, Stepanka P, Jan L, Ludmila T, Michal A, Marie C: HLA, NFKB1 and NFKBIA gene polymorphism profile in autoimmune diabetes mellitus patients. Exp Clin Endocrinol Diabetes. 2007, 115: 124-129. 10.1055/s-2007-949589.PubMed

101.

Kurylowicz A, Hiromatsu Y, Jurecka-Lubieniecka B, Kula D, Kowalska M, Ichimura M, Koga H, Kaku H, Bar-Andziak E, Nauman J, Jarzab B, Ploski R, Bednarczuk T: Association of NFKB1-94ins/del ATTG promoter polymorphism with susceptibility to and phenotype of Graves' disease. Genes Immun. 2007, 8: 532-538. 10.1038/sj.gene.6364418.PubMed

102.

Sha WC, Liou HC, Tuomanen EI, Baltimore D: Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell. 1995, 80: 321-330. 10.1016/0092-8674(95)90415-8.PubMed

103.

Emlen W, Niebur J, Kadera R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1994, 152: 3685-3692.PubMed

104.

Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR: Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum. 1998, 41: 1241-1250. 10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H.PubMed

105.

Karassa FB, Trikalinos TA, Ioannidis JP: The role of FcgammaRIIA and IIIA polymorphisms in autoimmune diseases. Biomed Pharmacother. 2004, 58: 286-291. 10.1016/j.biopha.2004.04.004.PubMed

106.

Clark MR, Stuart SG, Kimberly RP, Ory PA, Goldstein IM: A single amino acid distinguishes the high-responder from the low-responder form of Fc receptor II on human monocytes. Eur J Immunol. 1991, 21: 1911-1916. 10.1002/eji.1830210820.PubMed

107.

Fanciulli M, Norsworthy PJ, Petretto E, Dong R, Harper L, Kamesh L, Heward JM, Gough SC, de Smith A, Blakemore AI, Froguel P, Owen CJ, Pearce SH, Teixeira L, Guillevin L, Graham DS, Pusey CD, Cook HT, Vyse TJ, Aitman TJ: FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet. 2007, 39: 721-723. 10.1038/ng2046.PubMedCentralPubMed

108.

Bave U, Magnusson M, Eloranta ML, Perers A, Alm GV, Ronnblom L: Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol. 2003, 171: 3296-3302.PubMed

109.

Magnusson V, Johanneson B, Lima G, Odeberg J, Alarcon-Segovia D, Alarcon-Riquelme ME: Both risk alleles for FcgammaRIIA and FcgammaRIIIA are susceptibility factors for SLE: a unifying hypothesis. Genes Immun. 2004, 5: 130-137. 10.1038/sj.gene.6364052.PubMed

110.

Zohar R, Lee W, Arora P, Cheifetz S, McCulloch C, Sodek J: Single cell analysis of intracellular osteopontin in osteogenic cultures of fetal rat calvarial cells. J Cell Physiol. 1997, 170: 88-100. 10.1002/(SICI)1097-4652(199701)170:1<88::AID-JCP10>3.0.CO;2-K.PubMed

111.

Shinohara ML, Lu L, Bu J, Werneck MB, Kobayashi KS, Glimcher LH, Cantor H: Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol. 2006, 7: 498-506. 10.1038/ni1327.PubMedCentralPubMed

112.

Denhardt DT, Noda M: Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl. 1998, 30-31: 92-102. 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A.PubMed

113.

Pollack SB, Linnemeyer PA, Gill S: Induction of osteopontin mRNA expression during activation of murine NK cells. J Leukoc Biol. 1994, 55: 398-400.PubMed

114.

Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, Cantor H: Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000, 287: 860-864. 10.1126/science.287.5454.860.PubMed

115.

Lampe MA, Patarca R, Iregui MV, Cantor H: Polyclonal B cell activation by the Eta-1 cytokine and the development of systemic autoimmune disease. J Immunol. 1991, 147: 2902-2906.PubMed

116.

Scatena M, Liaw L, Giachelli CM: Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007, 27: 2302-2309. 10.1161/ATVBAHA.107.144824.PubMed

117.

Vogt MH, Lopatinskaya L, Smits M, Polman CH, Nagelkerken L: Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann Neurol. 2003, 53: 819-822. 10.1002/ana.10606.PubMed

118.

Comabella M, Pericot I, Goertsches R, Nos C, Castillo M, Blas Navarro J, Rio J, Montalban X: Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol. 2005, 158: 231-239. 10.1016/j.jneuroim.2004.09.004.PubMed

119.

Chiocchetti A, Indelicato M, Bensi T, Mesturini R, Giordano M, Sametti S, Castelli L, Bottarel F, Mazzarino MC, Garbarini L, Giacopelli F, Valesini G, Santoro C, Dianzani I, Ramenghi U, Dianzani U: High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation. Blood. 2004, 103: 1376-1382. 10.1182/blood-2003-05-1748.PubMed

120.

Wong CK, Lit LC, Tam LS, Li EK, Lam CW: Elevation of plasma osteopontin concentration is correlated with disease activity in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005, 44: 602-606. 10.1093/rheumatology/keh558.

121.

Xu G, Nie H, Li N, Zheng W, Zhang D, Feng G, Ni L, Xu R, Hong J, Zhang JZ: Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest. 2005, 115: 1060-1067.PubMedCentralPubMed

122.

Masutani K, Akahoshi M, Tsuruya K, Tokumoto M, Ninomiya T, Kohsaka T, Fukuda K, Kanai H, Nakashima H, Otsuka T, Hirakata H: Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum. 2001, 44: 2097-2106. 10.1002/1529-0131(200109)44:9<2097::AID-ART360>3.0.CO;2-6.PubMed

123.

Ohshima S, Yamaguchi N, Nishioka K, Mima T, Ishii T, Umeshita-Sasai M, Kobayashi H, Shimizu M, Katada Y, Wakitani S, Murata N, Nomura S, Matsuno H, Katayama R, Kon S, Inobe M, Uede T, Kawase I, Saeki Y: Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol. 2002, 29: 2061-2067.PubMed

124.

Sato T, Nakai T, Tamura N, Okamoto S, Matsuoka K, Sakuraba A, Fukushima T, Uede T, Hibi T: Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut. 2005, 54: 1254-1262. 10.1136/gut.2004.048298.PubMedCentralPubMed

125.

Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, Sobel RA, Lock C, Karpuj M, Pedotti R, Heller R, Oksenberg JR, Steinman L: The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 2001, 294: 1731-1735. 10.1126/science.1062960.PubMed

126.

Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, Steinman L: Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol. 2007, 8: 74-83. 10.1038/ni1415.PubMed

127.

Jansson M, Panoutsakopoulou V, Baker J, Klein L, Cantor H: Cutting edge: Attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J Immunol. 2002, 168: 2096-2099.PubMed

128.

Vogt MH, Floris S, Killestein J, Knol DL, Smits M, Barkhof F, Polman CH, Nagelkerken L: Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neuroimmunol. 2004, 155: 155-160. 10.1016/j.jneuroim.2004.06.007.PubMed

129.

Miyazaki T, Ono M, Qu WM, Zhang MC, Mori S, Nakatsuru S, Nakamura Y, Sawasaki T, Endo Y, Nose M: Implication of allelic polymorphism of osteopontin in the development of lupus nephritis in MRL/lpr mice. Eur J Immunol. 2005, 35: 1510-1520. 10.1002/eji.200425672.PubMed

130.

Forton AC, Petri MA, Goldman D, Sullivan KE: An osteopontin (SPP1) polymorphism is associated with systemic lupus erythematosus. Hum Mutat. 2002, 19: 459-10.1002/humu.9025.PubMed

131.

D'Alfonso S, Barizzone N, Giordano M, Chiocchetti A, Magnani C, Castelli L, Indelicato M, Giacopelli F, Marchini M, Scorza R, Danieli MG, Cappelli M, Migliaresi S, Bigliardo B, Sabbadini MG, Baldissera E, Galeazzi M, Sebastiani GD, Minisola G, Ravazzolo R, Dianzani U, Momigliano-Richiardi P: Two single-nucleotide polymorphisms in the 5' and 3' ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum. 2005, 52: 539-547. 10.1002/art.20808.PubMed

132.

Wuthrich RP, Fan X, Ritthaler T, Sibalic V, Yu DJ, Loffing J, Kaissling B: Enhanced osteopontin expression and macrophage infiltration in MRL-Fas(lpr) mice with lupus nephritis. Autoimmunity. 1998, 28: 139-150. 10.3109/08916939808996282.PubMed

133.

Steinman L, Martin R, Bernard C, Conlon P, Oksenberg JR: Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci. 2002, 25: 491-505. 10.1146/annurev.neuro.25.112701.142913.PubMed

134.

Barnes BJ, Richards J, Mancl M, Hanash S, Beretta L, Pitha PM: Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J Biol Chem. 2004, 279: 45194-45207. 10.1074/jbc.M400726200.PubMed

135.

Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, Taniguchi T: IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature. 2005, 434: 772-777. 10.1038/nature03464.PubMed

136.

Han S, Guthridge JM, Harley IT, Sestak AL, Kim-Howard X, Kaufman KM, Namjou B, Deshmukh H, Bruner G, Espinoza LR, Gilkeson GS, Harley JB, James JA, Nath SK: Osteopontin and systemic lupus erythematosus association: a probable gene-gender interaction. PLoS One. 2008, 3: e0001757-10.1371/journal.pone.0001757.PubMed

137.

Kariuki SN, Moore JG, Kirou KA, Crow MK, Utset TO, Niewold TB: Age- and gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus. Genes Immun. 2009, 10: 487-494. 10.1038/gene.2009.15.PubMedCentralPubMed

138.

Cowley BD, Ricardo SD, Nagao S, Diamond JR: Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats. Kidney Int. 2001, 60: 2087-2096. 10.1046/j.1523-1755.2001.00065.x.PubMed

139.

Matkovits T, Christakos S: Variable in vivo regulation of rat vitamin D-dependent genes (osteopontin, Ca, Mg-adenosine triphosphatase, and 25-hydroxyvitamin D₃ 24-hydroxylase): implications for differing mechanisms of regulation and involvement of multiple factors. Endocrinology. 1995, 136: 3971-3982. 10.1210/en.136.9.3971.PubMed

140.

Raziuddin A, Sarkar FH, Dutkowski R, Shulman L, Ruddle FH, Gupta SL: Receptors for human alpha and beta interferon but not for gamma interferon are specified by human chromosome 21. Proc Natl Acad Sci USA. 1984, 81: 5504-5508. 10.1073/pnas.81.17.5504.PubMedCentralPubMed

141.

Cunninghame Graham DS, Akil M, Vyse TJ: Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families. Rheumatology (Oxford). 2007, 46: 927-930. 10.1093/rheumatology/kel449.

142.

Hellquist A, Jarvinen TM, Koskenmies S, Zucchelli M, Orsmark-Pietras C, Berglind L, Panelius J, Hasan T, Julkunen H, D'Amato M, Saarialho-Kere U, Kere J: Evidence for genetic association and interaction between the TYK2 and IRF5 genes in systemic lupus erythematosus. J Rheumatol. 2009, 36: 1631-1638. 10.3899/jrheum.081160.PubMed

143.

Ban M, Goris A, Lorentzen AR, Baker A, Mihalova T, Ingram G, Booth DR, Heard RN, Stewart GJ, Bogaert E, Dubois B, Harbo HF, Celius EG, Spurkland A, Strange R, Hawkins C, Robertson NP, Dudbridge F, Wason J, De Jager PL, Hafler D, Rioux JD, Ivinson AJ, McCauley JL, Pericak-Vance M, Oksenberg JR, Hauser SL, Sexton D, Haines J, Sawcer S: Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur J Hum Genet. 2009, 17: 1309-1313. 10.1038/ejhg.2009.41.PubMedCentralPubMed

144.

Abelson AK, Delgado-Vega AM, Kozyrev SV, Sanchez E, Velazquez-Cruz R, Eriksson N, Wojcik J, Linga Reddy MV, Lima G, D'Alfonso S, Migliaresi S, Baca V, Orozco L, Witte T, Ortego-Centeno N, Abderrahim H, Pons-Estel BA, Gutierrez C, Suarez A, Gonzalez-Escribano MF, Martin J, Alarcon-Riquelme ME: STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann Rheum Dis. 2009, 68: 1746-1753. 10.1136/ard.2008.097642.PubMed

145.

Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, Lee AT, Chung SA, Ferreira RC, Pant PV, Ballinger DG, Kosoy R, Demirci FY, Kamboh MI, Kao AH, Tian C, Gunnarsson I, Bengtsson AA, Rantapaa-Dahlqvist S, Petri M, Manzi S, Seldin MF, Ronnblom L, Syvanen AC, Criswell LA, Gregersen PK, Behrens TW: Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med. 2008, 358: 900-909. 10.1056/NEJMoa0707865.PubMed

146.

Namjou B, Sestak AL, Armstrong DL, Zidovetzki R, Kelly JA, Jacob N, Ciobanu V, Kaufman KM, Ojwang JO, Ziegler J, Quismorio FP, Reiff A, Myones BL, Guthridge JM, Nath SK, Bruner GR, Mehrian-Shai R, Silverman E, Klein-Gitelman M, McCurdy D, Wagner-Weiner L, Nocton JJ, Putterman C, Bae SC, Kim YJ, Petri M, Reveille JD, Vyse TJ, Gilkeson GS, Kamen DL, et al: High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups. Arthritis Rheum. 2009, 60: 1085-1095. 10.1002/art.24387.PubMedCentralPubMed

147.

Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, de Bakker PI, Le JM, Lee HS, Batliwalla F, Li W, Masters SL, Booty MG, Carulli JP, Padyukov L, Alfredsson L, Klareskog L, Chen WV, Amos CI, Criswell LA, Seldin MF, Kastner DL, Gregersen PK: STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med. 2007, 357: 977-986. 10.1056/NEJMoa073003.PubMedCentralPubMed

148.

Sigurdsson S, Nordmark G, Garnier S, Grundberg E, Kwan T, Nilsson O, Eloranta ML, Gunnarsson I, Svenungsson E, Sturfelt G, Bengtsson AA, Jonsen A, Truedsson L, Rantapaa-Dahlqvist S, Eriksson C, Alm G, Goring HH, Pastinen T, Syvanen AC, Ronnblom L: A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum Mol Genet. 2008, 17: 2868-2876. 10.1093/hmg/ddn184.PubMedCentralPubMed

149.

Suarez-Gestal M, Calaza M, Endreffy E, Pullmann R, Ordi-Ros J, Domenico Sebastiani G, Ruzickova S, Jose Santos M, Papasteriades C, Marchini M, Skopouli FN, Suarez A, Blanco FJ, D'Alfonso S, Bijl M, Carreira P, Witte T, Migliaresi S, Gomez-Reino JJ, Gonzalez A: Replication of recently identified systemic lupus erythematosus genetic associations: a case-control study. Arthritis Res Ther. 2009, 11: R69-PubMedCentralPubMed

150.

Korman BD, Alba MI, Le JM, Alevizos I, Smith JA, Nikolov NP, Kastner DL, Remmers EF, Illei GG: Variant form of STAT4 is associated with primary Sjogren's syndrome. Genes Immun. 2008, 9: 267-270. 10.1038/gene.2008.1.PubMed

151.

Palomino-Morales RJ, Rojas-Villarraga A, Gonzalez CI, Ramirez G, Anaya JM, Martin J: STAT4 but not TRAF1/C5 variants influence the risk of developing rheumatoid arthritis and systemic lupus erythematosus in Colombians. Genes Immun. 2008, 9: 379-382. 10.1038/gene.2008.30.PubMed

152.

Kawasaki A, Ito I, Hikami K, Ohashi J, Hayashi T, Goto D, Matsumoto I, Ito S, Tsutsumi A, Koga M, Arinami T, Graham RR, Hom G, Takasaki Y, Hashimoto H, Behrens TW, Sumida T, Tsuchiya N: Role of STAT4 polymorphisms in systemic lupus erythematosus in a Japanese population: a case-control association study of the STAT1-STAT4 region. Arthritis Res Ther. 2008, 10: R113-10.1186/ar2516.PubMedCentralPubMed

153.

Kobayashi S, Ikari K, Kaneko H, Kochi Y, Yamamoto K, Shimane K, Nakamura Y, Toyama Y, Mochizuki T, Tsukahara S, Kawaguchi Y, Terai C, Hara M, Tomatsu T, Yamanaka H, Horiuchi T, Tao K, Yasutomo K, Hamada D, Yasui N, Inoue H, Itakura M, Okamoto H, Kamatani N, Momohara S: Association of STAT4 with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in the Japanese population. Arthritis Rheum. 2008, 58: 1940-1946. 10.1002/art.23494.PubMed

154.

Lee HS, Remmers EF, Le JM, Kastner DL, Bae SC, Gregersen PK: Association of STAT4 with rheumatoid arthritis in the Korean population. Mol Med. 2007, 13: 455-460.PubMedCentralPubMed

155.

Yang W, Ng P, Zhao M, Hirankarn N, Lau CS, Mok CC, Chan TM, Wong RW, Lee KW, Mok MY, Wong SN, Avihingsanon Y, Lee TL, Ho MH, Lee PP, Wong WH, Lau YL: Population differences in SLE susceptibility genes: STAT4 and BLK, but not PXK, are associated with systemic lupus erythematosus in Hong Kong Chinese. Genes Immun. 2009, 10: 219-226. 10.1038/gene.2009.1.PubMed

156.

Frucht DM, Aringer M, Galon J, Danning C, Brown M, Fan S, Centola M, Wu CY, Yamada N, El Gabalawy H, O'Shea JJ: Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation. J Immunol. 2000, 164: 4659-4664.PubMed

157.

Kaplan MH: STAT4: a critical regulator of inflammation in vivo. Immunol Res. 2005, 31: 231-242. 10.1385/IR:31:3:231.PubMed

158.

Nishikomori R, Usui T, Wu CY, Morinobu A, O'Shea JJ, Strober W: Activated STAT4 has an essential role in Th1 differentiation and proliferation that is independent of its role in the maintenance of IL-12R beta 2 chain expression and signaling. J Immunol. 2002, 169: 4388-4398.PubMed

159.

Mathur AN, Chang HC, Zisoulis DG, Stritesky GL, Yu Q, O'Malley JT, Kapur R, Levy DE, Kansas GS, Kaplan MH: Stat3 and Stat4 direct development of IL-17-secreting Th cells. J Immunol. 2007, 178: 4901-4907.PubMed

160.

Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000, 13: 715-725. 10.1016/S1074-7613(00)00070-4.PubMed

161.

Fortunato G, Calcagno G, Bresciamorra V, Salvatore E, Filla A, Capone S, Liguori R, Borelli S, Gentile I, Borrelli F, Borgia G, Sacchetti L: Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cytokine Res. 2008, 28: 141-152. 10.1089/jir.2007.0049.PubMed

162.

Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, et al: Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008, 40: 955-962. 10.1038/ng.175.PubMedCentralPubMed

163.

Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM, Tian C, Chung SA, Nititham J, Hom G, Kao AH, Demirci FY, Kamboh MI, Petri M, Manzi S, Kastner DL, Seldin MF, Gregersen PK, Behrens TW, Criswell LA: Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet. 2008, 4: e1000084-10.1371/journal.pgen.1000084.PubMedCentralPubMed

164.

Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB: Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol. 2009, 182: 34-38.PubMedCentralPubMed

165.

Miyagi T, Gil MP, Wang X, Louten J, Chu WM, Biron CA: High basal STAT4 balanced by STAT1 induction to control type 1 interferon effects in natural killer cells. J Exp Med. 2007, 204: 2383-2396. 10.1084/jem.20070401.PubMedCentralPubMed

166.

Kozyrev SV, Abelson AK, Wojcik J, Zaghlool A, Linga Reddy MV, Sanchez E, Gunnarsson I, Svenungsson E, Sturfelt G, Jonsen A, Truedsson L, Pons-Estel BA, Witte T, D'Alfonso S, Barizzone N, Danieli MG, Gutierrez C, Suarez A, Junker P, Laustrup H, Gonzalez-Escribano MF, Martin J, Abderrahim H, Alarcon-Riquelme ME: Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet. 2008, 40: 211-216. 10.1038/ng.79.PubMed

167.

Ito I, Kawasaki A, Ito S, Hayashi T, Goto D, Matsumoto I, Tsutsumi A, Hom G, Graham RR, Takasaki Y, Hashimoto H, Ohashi J, Behrens TW, Sumida T, Tsuchiya N: Replication of the association between the C8orf13-BLK region and systemic lupus erythematosus in a Japanese population. Arthritis Rheum. 2009, 60: 553-558. 10.1002/art.24246.PubMed

168.

Ito I, Kawasaki A, Ito S, Kondo Y, Sugihara M, Horikoshi M, Hayashi T, Goto D, Matsumoto I, Tsutsumi A, Takasaki Y, Hashimoto H, Matsuta K, Sumida T, Tsuchiya N: Replication of association between FAM167A(C8orf13)-BLK region and rheumatoid arthritis in a Japanese population. Ann Rheum Dis. 2009, doi:10.1136/ard.2009.118760.

169.

Yin H, Borghi MO, Delgado-Vega AM, Tincani A, Meroni PL, Alarcon-Riquelme ME: Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. Arthritis Rheum. 2009, 60: 2468-2471. 10.1002/art.24701.PubMed

170.

Portis T, Dyck P, Longnecker R: Epstein-Barr Virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2003, 102: 4166-4178. 10.1182/blood-2003-04-1018.PubMed

171.

Guo L, Deshmukh H, Lu R, Vidal GS, Kelly JA, Kaufman KM, Dominguez N, Klein W, Kim-Howard X, Bruner GR, Scofield RH, Moser KL, Gaffney PM, Dozmorov IM, Gilkeson GS, Wakeland EK, Li QZ, Langefeld CD, Marion MC, Williams AH, Divers J, Alarcon GS, Brown EE, Kimberly RP, Edberg JC, Ramsey-Goldman R, Reveille JD, McGwin G, Vila LM, Petri MA, et al: Replication of the BANK1 genetic association with systemic lupus erythematosus in a European-derived population. Genes Immun. 2009, 10: 531-538. 10.1038/gene.2009.18.PubMedCentralPubMed

172.

Chang YK, Yang W, Zhao M, Mok CC, Chan TM, Wong RW, Lee KW, Mok MY, Wong SN, Ng IO, Lee TL, Ho MH, Lee PP, Wong WH, Lau CS, Sham PC, Lau YL: Association of BANK1 and TNFSF4 with systemic lupus erythematosus in Hong Kong Chinese. Genes Immun. 2009, 10: 414-420. 10.1038/gene.2009.16.PubMedCentralPubMed

173.

Orozco G, Abelson AK, Gonzalez-Gay MA, Balsa A, Pascual-Salcedo D, Garcia A, Fernandez-Gutierrez B, Petersson I, Pons-Estel B, Eimon A, Paira S, Scherbarth HR, Alarcon-Riquelme M, Martin J: Study of functional variants of the BANK1 gene in rheumatoid arthritis. Arthritis Rheum. 2009, 60: 372-379. 10.1002/art.24244.PubMed

174.

Yokoyama K, Su Ih IH, Tezuka T, Yasuda T, Mikoshiba K, Tarakhovsky A, Yamamoto T: BANK regulates BCR-induced calcium mobilization by promoting tyrosine phosphorylation of IP(3) receptor. EMBO J. 2002, 21: 83-92. 10.1093/emboj/21.1.83.PubMedCentralPubMed

175.

Delgado-Vega AM, Castillejo-López C, Wojcik J, Kozyrev S, Sánchez E, Pöllmann D, López-Egido JR, Fineschi S, Domínguez N, Lu R, James JA, Merrill JT, Kelly JA, Kaufman KM, Moser K, Gilkeson G, Frostegård J, Pons-Estel BA, D'Alfonso S, Witte T, Callejas JL, Harley J, Gaffney P, Martin J, Guthridge JM, Alarcón-Riquelme ME: Genetic interactions reveal a novel B-cell pathway in systemic lupus erythematosus [abstract/presentation #272]. Proceedings of the 59th Annual Meeting of The American Society of Human Genetics; October 24 2009; Honolulu, HI. 2009, The American Society of Human Genetics, Bethesda, MD, USA, [http://www.ashg.org/2009meeting/abstracts/fulltext/]

176.

Lu R, Vidal GS, Kelly JA, Delgado-Vega AM, Howard XK, Macwana SR, Dominguez N, Klein W, Burrell C, Harley IT, Kaufman KM, Bruner GR, Moser KL, Gaffney PM, Gilkeson GS, Wakeland EK, Li QZ, Langefeld CD, Marion MC, Divers J, Alarcon GS, Brown EE, Kimberly RP, Edberg JC, Ramsey-Goldman R, Reveille JD, McGwin G, Vila LM, Petri MA, Bae SC, et al: Genetic associations of LYN with systemic lupus erythematosus. Genes Immun. 2009, 10: 397-403. 10.1038/gene.2009.19.PubMedCentralPubMed

177.

Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RA: Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum. 2005, 52: 3955-3965. 10.1002/art.21416.PubMed

178.

Davidson A, Diamond B: Autoimmune diseases. N Engl J Med. 2001, 345: 340-350. 10.1056/NEJM200108023450506.PubMed

179.

Yasutomo K, Horiuchi T, Kagami S, Tsukamoto H, Hashimura C, Urushihara M, Kuroda Y: Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet. 2001, 28: 313-314. 10.1038/91070.PubMed

180.

Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee YA, de Silva U, Bailey SL, Witte T, Vyse TJ, Kere J, Pfeiffer C, Harvey S, Wong A, Koskenmies S, Hummel O, Rohde K, Schmidt RE, Dominiczak AF, Gahr M, Hollis T, Perrino FW, Lieberman J, Hubner N: Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet. 2007, 39: 1065-1067. 10.1038/ng2091.PubMed

181.

Kavanagh D, Spitzer D, Kothari PH, Shaikh A, Liszewski MK, Richards A, Atkinson JP: New roles for the major human 3'-5' exonuclease TREX1 in human disease. Cell Cycle. 2008, 7: 1718-1725. 10.4161/cc.7.12.6162.PubMedCentralPubMed

182.

1000 Genomes Project. [http://www.1000genomes.org/]

183.

Smyth DJ, Cooper JD, Bailey R, Field S, Burren O, Smink LJ, Guja C, Ionescu-Tirgoviste C, Widmer B, Dunger DB, Savage DA, Walker NM, Clayton DG, Todd JA: A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet. 2006, 38: 617-619. 10.1038/ng1800.PubMed

184.

Martinez A, Varade J, Lamas JR, Fernandez-Arquero M, Jover JA, de la Concha EG, Fernandez-Gutierrez B, Urcelay E: Association of the IFIH1-GCA-KCNH7 chromosomal region with rheumatoid arthritis. Ann Rheum Dis. 2008, 67: 137-138. 10.1136/ard.2007.073213.PubMed

185.

Martinez A, Santiago JL, Cenit MC, de Las Heras V, de la Calle H, Fernandez-Arquero M, Arroyo R, de la Concha EG, Urcelay E: IFIH1-GCA-KCNH7 locus: influence on multiple sclerosis risk. Eur J Hum Genet. 2008, 16: 861-864. 10.1038/ejhg.2008.16.PubMed

186.

Sutherland A, Davies J, Owen CJ, Vaikkakara S, Walker C, Cheetham TD, James RA, Perros P, Donaldson PT, Cordell HJ, Quinton R, Pearce SH: Genomic polymorphism at the interferon-induced helicase (IFIH1) locus contributes to Graves' disease susceptibility. J Clin Endocrinol Metab. 2007, 92: 3338-3341. 10.1210/jc.2007-0173.PubMed

187.

Shigemoto T, Kageyama M, Hirai R, Zheng J, Yoneyama M, Fujita T: Identification of loss of function mutations in human genes encoding RIG-I and MDA5: implications for resistance to type I diabetes. J Biol Chem. 2009, 284: 13348-13354. 10.1074/jbc.M809449200.PubMedCentralPubMed

188.

Miceli-Richard C, Gestermann N, Ittah M, Comets E, Loiseau P, Puechal X, Hachulla E, Gottenberg JE, Lebon P, Becquemont L, Mariette X: The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjogren's syndrome. Arthritis Rheum. 2009, 60: 1991-1997. 10.1002/art.24662.PubMed

189.

Orozco G, Alizadeh BZ, Delgado-Vega AM, Gonzalez-Gay MA, Balsa A, Pascual-Salcedo D, Fernandez-Gutierrez B, Gonzalez-Escribano MF, Petersson IF, van Riel PL, Barrera P, Coenen MJ, Radstake TR, van Leeuwen MA, Wijmenga C, Koeleman BP, Alarcon-Riquelme M, Martin J: Association of STAT4 with rheumatoid arthritis: a replication study in three European populations. Arthritis Rheum. 2008, 58: 1974-1980. 10.1002/art.23549.PubMed

190.

Zervou MI, Goulielmos GN, Castro-Giner F, Tosca AD, Krueger-Krasagakis S: STAT4 gene polymorphism is associated with psoriasis in the genetically homogeneous population of Crete, Greece. Hum Immunol. 2009, 70: 738-741. 10.1016/j.humimm.2009.05.008.PubMed

191.

Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, Hurley P, Chien M, Chai S, Hitotsumatsu O, McNally E, Pickart C, Ma A: The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol. 2004, 5: 1052-1060. 10.1038/ni1110.PubMed

192.

Feng XB, Shen N, Qian J, Sun L, Hua J, Chen SL: Single nucleotide polymorphisms of deoxyribonuclease I and their expression in Chinese systemic lupus erythematosus patients. Chin Med J (Engl). 2004, 117: 1670-1676.

193.

Dittmar M, Bischofs C, Matheis N, Poppe R, Kahaly GJ: A novel mutation in the DNASE1 gene is related with protein instability and decreased enzyme activity in thyroid autoimmunity. J Autoimmun. 2009, 32: 7-13. 10.1016/j.jaut.2008.09.005.PubMed

194.

Bodano A, Gonzalez A, Ferreiros-Vidal I, Balada E, Ordi J, Carreira P, Gomez-Reino JJ, Conde C: Association of a non-synonymous single-nucleotide polymorphism of DNASEI with SLE susceptibility. Rheumatology (Oxford). 2006, 45: 819-823. 10.1093/rheumatology/kel019.

195.

Yokoi N, Fujiwara Y, Wang HY, Kitao M, Hayashi C, Someya T, Kanamori M, Oiso Y, Tajima N, Yamada Y, Seino Y, Ikegami H, Seino S: Identification and functional analysis of CBLB mutations in type 1 diabetes. Biochem Biophys Res Commun. 2008, 368: 37-42. 10.1016/j.bbrc.2008.01.032.PubMed

196.

Donn RP, Barrett JH, Farhan A, Stopford A, Pepper L, Shelley E, Davies N, Ollier WE, Thomson W: Cytokine gene polymorphisms and susceptibility to juvenile idiopathic arthritis. British Paediatric Rheumatology Study Group. Arthritis Rheum. 2001, 44: 802-810. 10.1002/1529-0131(200104)44:4<802::AID-ANR136>3.0.CO;2-G.PubMed

197.

Morrison VA, Onengut-Gumuscu S, Concannon P: A functional variant of IRS1 is associated with type 1 diabetes in families from the US and UK. Mol Genet Metab. 2004, 81: 291-294. 10.1016/j.ymgme.2003.10.018.PubMed

198.

De Jager PL, Franchimont D, Waliszewska A, Bitton A, Cohen A, Langelier D, Belaiche J, Vermeire S, Farwell L, Goris A, Libioulle C, Jani N, Dassopoulos T, Bromfield GP, Dubois B, Cho JH, Brant SR, Duerr RH, Yang H, Rotter JI, Silverberg MS, Steinhart AH, Daly MJ, Podolsky DK, Louis E, Hafler DA, Rioux JD: The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun. 2007, 8: 387-397. 10.1038/sj.gene.6364398.PubMed

199.

Castiblanco J, Varela DC, Castano-Rodriguez N, Rojas-Villarraga A, Hincapie ME, Anaya JM: TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infect Genet Evol. 2008, 8: 541-544. 10.1016/j.meegid.2008.03.001.PubMed

200.

Jacob CO, Zhu J, Armstrong DL, Yan M, Han J, Zhou XJ, Thomas JA, Reiff A, Myones BL, Ojwang JO, Kaufman KM, Klein-Gitelman M, McCurdy D, Wagner-Weiner L, Silverman E, Ziegler J, Kelly JA, Merrill JT, Harley JB, Ramsey-Goldman R, Vila LM, Bae SC, Vyse TJ, Gilkeson GS, Gaffney PM, Moser KL, Langefeld CD, Zidovetzki R, Mohan C: Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci USA. 2009, 106: 6256-6261. 10.1073/pnas.0901181106.PubMedCentralPubMed

201.

Radstake TR, Franke B, Hanssen S, Netea MG, Welsing P, Barrera P, Joosten LA, van Riel PL, Berg van den WB: The Toll-like receptor 4 Asp299Gly functional variant is associated with decreased rheumatoid arthritis disease susceptibility but does not influence disease severity and/or outcome. Arthritis Rheum. 2004, 50: 999-1001. 10.1002/art.20114.PubMed

202.

Palomino-Morales R, Torres O, Vazquez-Rodriguez TR, Morado IC, Castaneda S, Callejas-Rubio JL, Miranda-Filloy JA, Fernandez-Gutierrez B, Martin J, Gonzalez-Gay MA: Association between toll-like receptor 4 gene polymorphism and biopsy-proven giant cell arteritis. J Rheumatol. 2009, 36: 1501-1506. 10.3899/jrheum.081286.PubMed

203.

Hirankarn N, Tangwattanachuleeporn M, Wongpiyabovorn J, Wongchinsri J, Avihingsanon Y: Genetic association of interferon-alpha subtypes 1, 2 and 5 in systemic lupus erythematosus. Tissue Antigens. 2008, 72: 588-592. 10.1111/j.1399-0039.2008.01146.x.PubMed

204.

Miterski B, Jaeckel S, Epplen JT, Pohlau D, Hardt C: The interferon gene cluster: a candidate region for MS predisposition? Multiple Sclerosis Study Group. Genes Immun. 1999, 1: 37-44. 10.1038/sj.gene.6363634.PubMed

205.

Leyva L, Fernandez O, Fedetz M, Blanco E, Fernandez VE, Oliver B, Leon A, Pinto-Medel MJ, Mayorga C, Guerrero M, Luque G, Alcina A, Matesanz F: IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol. 2005, 163: 165-171. 10.1016/j.jneuroim.2005.02.010.PubMed

206.

Tao K, Fujii M, Tsukumo S, Maekawa Y, Kishihara K, Kimoto Y, Horiuchi T, Hisaeda H, Akira S, Kagami S, Yasutomo K: Genetic variations of Toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population. Ann Rheum Dis. 2007, 66: 905-909. 10.1136/ard.2006.065961.PubMedCentralPubMed

Titel: Genetic associations in type I interferon related pathways with autoimmunity
verfasst von: Angélica M Delgado-Vega
Marta E Alarcón-Riquelme
Sergey V Kozyrev
Publikationsdatum: 01.04.2010
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe Sonderheft 1/2010
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar2883

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2010

Overview of the biology of type I interferons

Type I interferon in organ-targeted autoimmune and inflammatory diseases

Potential role of IFNα in adult lupus

Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus

Type 1 interferons and myositis